[go: up one dir, main page]

AR088729A1 - Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica - Google Patents

Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica

Info

Publication number
AR088729A1
AR088729A1 ARP120101017A ARP120101017A AR088729A1 AR 088729 A1 AR088729 A1 AR 088729A1 AR P120101017 A ARP120101017 A AR P120101017A AR P120101017 A ARP120101017 A AR P120101017A AR 088729 A1 AR088729 A1 AR 088729A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
methyl
halogen
carbamoyl
Prior art date
Application number
ARP120101017A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR088729A1 publication Critical patent/AR088729A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de 3-ureidoisoquinolin-8-ilo de la fórmula (1) útiles en prevención o tratamiento de enfermedades bacterianas. Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ es alquilo C₁₋₃, haloalquilo C₂₋₃ o ciclopropilo; R² es H, halógeno, piridazin-4-ilo, pirimidin-5-ilo o un grupo que tiene la fórmula (2), (3) ó (4), en donde Rˣ es H y cada uno de Rʸ y Rᶻ es independientemente H o metilo, o cada uno de Rˣ y Rᶻ es H y Rʸ es halógeno, ciano, alquilo C₂₋₄, alcoxi C₁₋₄, amino, hidroxi, hidroxi-alquilo C₁₋₃, trifluorometilo, carbamoilo, carbamoil-alquilo C₁₋₂, (metilcarbamoil)-alquilo C₁₋₂, (dimetilcarbamoil)-alquilo C₁₋₂, terc-butoxicarbonilmetilo, ciclopropilo, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-1-ilo o 1-morfolinometilo, o Rˣ es H y cada uno de Rʸ y Rᶻ es independientemente halógeno, o Rˣ es metilo, Rʸ es metilo o halógeno y Rᶻ es H, o Rˣ es metilo o halógeno, Rʸ es H y Rᶻ es metilo o halógeno, o Rˣ es metilo o halógeno y cada uno de Rʸ y Rᶻ es H; Rˣ² es H, amino o hidroximetilo; Rˣ³ es hidroxi, carboxi, carbamoilo, hidroximetilo o aminometilo, Rʸ³ es H y Rᶻ³ es H o cada uno de Rˣ³ y Rᶻ³ es H y Rʸ³ es hidroxi, acetamidometilo, (dimetilamino)metilo, carboximetilo, carbamoilo o aminometilo, o cada uno de Rˣ³ y Rʸ³ es H y Rᶻ³ es hidroxi; R³ es alquilo C₁₋₄, alquinilo C₂₋₄, amino-alquilo C₁₋₃, carbamoil-alquilo C₁₋₃, (metilcarbamoil)-alquilo C₁₋₃, alcoxi C₁₋₄, haloalcoxi C₁₋₄, alquiniloxi C₃₋₄, (4-hidroxibut-2-en-1-il)oxi, (4-aminobut-2-en-1-il)oxi, dimetilamino-alcoxi C₂₋₃, carbamoil-alcoxi C₁₋₃, alquilamino C₁₋₃, cicloalquilo C₃₋₆, cicloalquil C₃₋₆-alquilo C₁₋₄, cicloalquil C₃₋₆-alcoxi C₁₋₄, hidroxi-alquilo C₁₋₃, hidroxi-alcoxi C₂₋₃, alcoxi C₁₋₃-alquilo C₁₋₃, alcoxi C₁₋₃-alcoxi C₁₋₃, carboxi-alquilo C₁₋₃, carboxi-alcoxi C₁₋₃, alcoxicarbonil C₁₋₂-alcoxi C₁₋₃, arilo, heteroarilo C₅₋₆, bencilo, benciloxi, 2-cianoetoxi, 2,3-dihidroxipropoxi, 3,4-dihidroxibutoxi, -CH₂Rᵃ, -CH₂CH₂Rᵇ, -(CH₂)ₙ-C(O)O-Rᵈ, (CH₂)ₙ-N(Rᶜ)C(O)O-Rᵈ, -O-(CH₂)ₙ-N(Rᶜ)C(O)O-Rᵈ, -(CH₂)ₙ-Rᵉ o -O-(CH₂)ₙ-Rᵉ; n es 1, 2 ó 3; Rᵃ es ciano, acetilamino, N,N-dimetilamino; y Rᵇ es ciano; Rᶜ es H o metilo; Rᵈ es alquilo C₁₋₄; Rᵉ es pirrolidin-1-ilo, piperidin-1-ilo, piperidin-3-ilo, morfolin-1-ilo, 2-oxopirrolidin-1-ilo, 5-oxopirrolidin-2-ilo, 2,5-dioxopirrolidin-1-ilo, 2-oxoimidazoliden-1-ilo, 4-(terc-butoxicarbonil)piperazin-1-ilo, 4-(aminometil)ciclohexilo o heteroarilo C₅₋₆; R⁴ es H o metilo; o una sal de dicho compuesto.
ARP120101017A 2011-03-29 2012-03-27 Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica AR088729A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011051320 2011-03-29
IB2011054063 2011-09-16

Publications (1)

Publication Number Publication Date
AR088729A1 true AR088729A1 (es) 2014-07-02

Family

ID=45976978

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101017A AR088729A1 (es) 2011-03-29 2012-03-27 Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica

Country Status (17)

Country Link
US (1) US8889676B2 (es)
EP (1) EP2691373A1 (es)
JP (1) JP2014512352A (es)
KR (1) KR20140019423A (es)
CN (1) CN103476756A (es)
AR (1) AR088729A1 (es)
AU (1) AU2012235706A1 (es)
BR (1) BR112013024899A2 (es)
CA (1) CA2828423A1 (es)
IL (1) IL228486A0 (es)
MA (1) MA35048B1 (es)
MX (1) MX2013011253A (es)
PH (1) PH12013501981A1 (es)
RU (1) RU2013147875A (es)
TW (1) TW201249801A (es)
WO (1) WO2012131588A1 (es)
ZA (1) ZA201308049B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019133662A (ru) 2017-03-24 2021-04-26 Тайсо Фармасьютикал Ко., Лтд. Производное 2(1h)-хинолинона
CN114846009B (zh) 2019-12-24 2023-12-12 杭州中美华东制药有限公司 具有khk抑制作用的化合物
JP2023044027A (ja) * 2021-09-17 2023-03-30 三井化学株式会社 抗菌剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
DE60024631T2 (de) 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
DE60139964D1 (de) 2000-12-15 2009-10-29 Vertex Pharma Bakterielle Gyrase-Hemmer sowie deren Verwendung
US6831068B2 (en) 2002-02-13 2004-12-14 Abbott Laboratories Macrolide antibacterial compounds
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
RU2333208C2 (ru) 2002-06-13 2008-09-10 Вертекс Фармасьютикалз Инкорпорейтед Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
ES2328047T3 (es) 2004-03-19 2009-11-06 Warner-Lambert Company Llc Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos.
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
WO2006049941A2 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CN1958568B (zh) * 2005-11-03 2011-04-13 中国科学院上海药物研究所 一类预防或治疗幽门螺杆菌感染化合物、其制法和用途
AU2006311729A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換2−アミノ縮合複素環式化合物
WO2007146230A2 (en) * 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
KR20090086629A (ko) 2006-12-04 2009-08-13 아스트라제네카 아베 항박테리아성 폴리시클릭 우레아 화합물
CA2672940A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008141010A2 (en) 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
WO2009027732A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
WO2009089083A1 (en) 2008-01-04 2009-07-16 Abbott Laboratories Trpa1 antagonists
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
AU2009260447B2 (en) 2008-05-30 2012-03-29 Amgen Inc. Inhibitors of PI3 kinase
US20090325902A1 (en) 2008-06-04 2009-12-31 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
EP2303894A1 (en) 2008-06-04 2011-04-06 AstraZeneca AB Thiazolo [5, 4-b] pyridine and oxazolo [5, 4-b] pyridine derivatives as antibacterial agents
BRPI0915471A2 (pt) 2008-06-04 2017-06-27 Astrazeneca Ab composto, composição farmacêutica, métodos de inibir dna girase bacteriana e/ou topoisomerase bacteriana iv, para produzir um efeito antibacteriano em um animal de sangue quente e para tratar uma infecção bacteriana em um animal de sangue quente, e, uso de um composto
US20110166088A1 (en) 2008-06-25 2011-07-07 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
UY32694A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Derivados heterocíclicos de urea y métodos de uso de los mismos
AR077971A1 (es) 2009-08-26 2011-10-05 Astrazeneca Ab Derivados heterociclicos de urea y metodos de uso de los mismos
KR20130012072A (ko) 2010-03-31 2013-01-31 액테리온 파마슈티칼 리미티드 항박테리아성 이소퀴놀린-3-일우레아 유도체

Also Published As

Publication number Publication date
AU2012235706A1 (en) 2013-11-14
CN103476756A (zh) 2013-12-25
US20140038961A1 (en) 2014-02-06
IL228486A0 (en) 2013-12-31
NZ617068A (en) 2015-05-29
ZA201308049B (en) 2016-08-31
JP2014512352A (ja) 2014-05-22
MA35048B1 (fr) 2014-04-03
RU2013147875A (ru) 2015-05-10
KR20140019423A (ko) 2014-02-14
US8889676B2 (en) 2014-11-18
WO2012131588A1 (en) 2012-10-04
EP2691373A1 (en) 2014-02-05
PH12013501981A1 (en) 2013-11-25
MX2013011253A (es) 2013-10-17
BR112013024899A2 (pt) 2016-12-20
CA2828423A1 (en) 2012-10-04
TW201249801A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
ES2625256T3 (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
AR085195A1 (es) Metodo de tratamiento de cancer
AR082101A1 (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento
NZ607794A (en) N-acylsulfonamide apoptosis promoters
MY182539A (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
MD4425B1 (ro) Alcoxipirazoli în calitate de activatori ai guanilatciclazei solubile
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
RU2017126128A (ru) Конденсированные бициклические соединения для лечения заболевания
BR112013010552A2 (pt) derivado de piridina e agente medicinal
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
BR112014010420A2 (pt) inibidores de pak para o tratamento de distúrbios proliferativos celulares
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
AR084637A1 (es) Compuestos heterociclicos apropiados para el tratamiento de la dislipidemia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal